Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Take glucagon-like peptide-1 receptor agonists (GLP-1s ... DiMarchi smashed the prevailing view that changing natural human sequence was a "risky proposition more likely to increase toxicity ...

such as glucagon-like peptide-1, free fatty acids, and catecholamines. With this knowledge, scientists are seeking to better understand the role of GPCRs in islet biology and hormone secretion ...

For example, the company is developing an NIPEP-TPP anti-mutant KRAS antibody that binds the G12C mutant form of the human KRAS ... hormone (PTH) or glucagon-like peptide-1 (GLP-1) receptor ...